Why does reimbursement of orphan drugs require a specific approach?

Journal Title: OncoReview - Year 2011, Vol 1, Issue 1

Abstract

The greatest problem concerning the reimbursement of orphan products is their high price. In the case of orphan drugs, reimbursement and pricing decisions are highly interrelated. In decisions concerning reimbursement of newly marketed health technologies, their cost-effectiveness or cost-utility should be taken into account. Rigorousness and thoroughness of evaluating an orphan drug prior to a reimbursement or pricing decision should depend on the cost of treatment and it should be stressed that for most orphan interventions costs of treatment depends mainly on the price of the orphan product. Low cost orphan drugs should be managed as all other drugs which do not generate high treatment costs. In the case of high and very high cost orphan drugs much more restrictive procedures should be applied in its assessment. Apparently, assessment of a very high cost orphan drug should be performed and appropriate analyses should be prepared by the applicant. Alternatively, the technology may be assessed by the HTA Agency itself. Appraisal should be performed by a separate advisory body, e.g. The Rare Diseases Team to the Minister of Health. The final decision should be made by the Minister of Health, who will bear political responsibility. In Poland appropriate state authorities have to undertake specific professional pricing activities with respect to orphan products in egalitarian approach and introduce risk sharing agreements by Law.

Authors and Affiliations

Krzysztof Łanda, Jakub Adamski

Keywords

Related Articles

The role of histopathological examination, therapeutic difficulties and thromboembolism treatment during palliative chemotherapy in patient with antithrombin deficiency , colon cancer and endometrial cancer

Palliative chemotherapy in patients with thrombophilia is a challenge for clinical oncologists. On one hand the optimal treatment should be very safe for patient, on the other hand – as effective as possible. That therap...

Adjuvant imatinib after resection of gastrointestinal stromal tumour – systematic review and meta-analysis

[b]Background[/b]: Adjuvant therapy is recommended for the population of patients with high risk of recurrence of gastrointestinal stromal tumour after resection.[b]The aim of the study[/b]: Evaluation of the clinical ef...

Percutaneous retrieval of a fractured portacath fragment in two patients undergoing long-term chemotherapy

The paper discusses two clinical cases of cancer patients undergoing chemotherapy, in whom fractured and displaced tips of portacath catheters were revealed based on plain chest imaging. In the first case, the portacath...

High risk pulmonary embolism in oncology

Pulmonary embolism is a frequent complication of both cancer and the oncologic therapy. There is still discussed the subject of optimal antithrombotic prophylaxis in oncology. This article presents the patient with metas...

Jakość życia w onkologii i jakość życia w trakcie leczenia ukierunkowanego molekularnie chorych z rozpoznaniem rozsianego raka nerki

Dzięki wprowadzeniu do praktyki klinicznej leków ukierunkowanych molekularnie w ostatnich latach dokonał się znaczący postęp w leczeniu farmakologicznym zaawansowanego raka nerki. Obecnie jest zarejestrowanych sześć prep...

Download PDF file
  • EP ID EP53087
  • DOI -
  • Views 314
  • Downloads 0

How To Cite

Krzysztof Łanda, Jakub Adamski (2011). Why does reimbursement of orphan drugs require a specific approach?. OncoReview, 1(1), -. https://europub.co.uk/articles/-A-53087